In conjunction with the Society of NeuroInterventional Surgery (SNIS)

A new era for patients with Medium Vessel Occlusion 

DISTALS results mark a turning point in MVO—showing TIGERTRIEVER™ 13 restores blood flow

safely, with a consistent trend toward better outcomes, expanding what’s possible for nearly 50% of ischemic stroke patients.

The Positive Primary Endpoint Is In 

DISTALS and TIGERTRIEVER™ 13 delivered 3x improvement in successful reperfusion without symptomatic intracranial hemorrhage (sICH) events.

View more Trial results

More patients return to life with little to no disability​

With TIGERTRIEVER™ 13, outcomes

consistently trended toward better

recovery at 90 days.​

2x more patients reported perfect health​

on a patient-reported quality of life survey (EQ-5D)

a Pivotal moment

Finally, evidence from the first device and trial specifically designed for the delicate anatomy of distal stroke introduce a new interventional option for patients.

A distal-specific device​

TIGERTRIEVER 13 is the only thrombectomy system designed to actively adjust to the vessel anatomy. 

Flow restoration with maintained safety

TIGERTRIEVER 13 restored more blood flow to the brain, with no observed increase in sICH risk compared with medical management.

A more meaningful measure of recovery

DISTALS measured whether blood reached the brain tissue (CT perfusion). More blood flow to the brain was linked to a trend toward better recovery.

FDA-approved DMVO IDE study

Independent imaging core lab and strict oversight

Engineered for smaller vessels 

The only adjustable microtriever—TIGERTRIEVER 13 adapts to the vessel every time, optimizing clot engagement while minimizing stress.

DISTALS and TIGERTRIEVER 13 offer patients a chance at immediate reperfusion without adding measurable safety risk.

TIGERTRIEVER™ 13 is not indicated for DMVO in all markets. Refer to the appropriate IFU for indications and contraindications. 


References: 

  1. Goyal M, Ospel JM, Ganesh A, et al. Endovascular Treatment of Stroke Due to Medium-Vessel Occlusion. N Engl J Med. 2025;392(14):1385-1395. doi:10.1056/NEJMoa2411668 
  2. Psychogios M, Brehm A, Ribo M, et al. Endovascular Treatment for Stroke Due to Occlusion of Medium or Distal Vessels. N Engl J Med. 2025;392(14):1374-1384. doi:10.1056/NEJMoa2408954 
  3. DISCOUNT Trial. Presented at the International Stroke Conference (ISC); February 2025; Los Angeles, CA.